PURPOSE Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine
kinase inhibitor (TKI) therapy, resistance remains an obstacle. The most common …

Introduction: BCR-ABL1 kinase domain mutations represent the most frequent mechanism of
resistance to tyrosine kinase inhibitor (TKI) therapy, being detected in 40%–50% of imatinib …

Discovery of imatinib mesylate (IM) as the targeted BCR-ABL protein tyrosine kinase
inhibitor (TKI) has resulted in its use as the frontline therapy for chronic myeloid leukemia …

Mutations of the BCR-ABL1 kinase domain seem to be the most common cause of imatinib
mesylate resistance in chronic myeloid leukemia (CML). We screened BCR-ABL1 kinase …

Clinical resistance to imatinib (IM) in chronic myeloid leukemia (CML) carries adverse
consequences. We investigated 22 CML patients who developed IM-resistance for BCR …

The introduction of tyrosine kinase inhibitors has revolutionized the treatment of chronic
myeloid leukemia (CML). Imatinib mesylate, which competitively targets the adenosine 5 …

Philadelphia chromosome/BCR‐ABL 1 positive chronic myeloid leukaemia (CML) can be
successfully treated with Glivec (Imatinib), which is available free of cost through the Glivec …

In imatinib-treated patients with chronic myeloid leukemia (CML), BCR–ABL mutations are
the most common mechanism of resistance. Here we report the first multicenter Argentinean …

Abstract Development of resistance to imatinib mesylate (IM) in chronic myeloid leukemia
(CML) patients is mediated by different mechanisms that can be classified as BCR-ABL …

Since their introduction in 2001, tyrosine kinase inhibitors (TKIs) targeting BCR-ABL have
become the standard therapy for chronic myeloid leukaemia (CML). While allogeneic …